BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38395797)

  • 21. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
    Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
    J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. (99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor.
    Liu Y; Lan X; Wu T; Lang J; Jin X; Sun X; Wen Q; An R
    Nucl Med Biol; 2014 Jul; 41(6):450-6. PubMed ID: 24768147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
    Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J
    J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Shi L; Chen B; Liu T; Li L; Hu B; Li C; Jia B; Wang F
    Mol Pharm; 2022 Jul; 19(7):2583-2594. PubMed ID: 35696536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis of a novel
    Jiao H; Zhao X; Han J; Zhang J; Wang J
    Int J Radiat Biol; 2020 Nov; 96(11):1443-1451. PubMed ID: 32809887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inter-rater and intra-rater agreement of [
    Hughes DJ; Chand G; Johnson J; Bailey D; Adamson K; Goh V; Cook GJR
    EJNMMI Res; 2023 May; 13(1):51. PubMed ID: 37256434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
    Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
    J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of [(99m)Tc]Duramycin as a SPECT Imaging Agent for Early Assessment of Tumor Apoptosis.
    Elvas F; Vangestel C; Rapic S; Verhaeghe J; Gray B; Pak K; Stroobants S; Staelens S; Wyffels L
    Mol Imaging Biol; 2015 Dec; 17(6):838-47. PubMed ID: 25896815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical Evaluation of
    Shi D; Fu W; Tan H; Lin Q; Shi H; Cheng D
    Mol Pharm; 2024 Jan; 21(1):303-312. PubMed ID: 38109713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [
    Konrad M; Rinscheid A; Wienand G; Nittbaur B; Wester HJ; Janzen T; Lapa C; Pfob CH; Schottelius M
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3937-3948. PubMed ID: 37597009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT.
    Zeven K; De Groof TWM; Ceuppens H; Awad RM; Ertveldt T; de Mey W; Meeus F; Raes G; Breckpot K; Devoogdt N
    Front Immunol; 2023; 14():1268900. PubMed ID: 37799715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking.
    Li L; Liu T; Shi L; Zhang X; Guo X; Hu B; Yao M; Zhu H; Yang Z; Jia B; Wang F
    Theranostics; 2022; 12(12):5551-5563. PubMed ID: 35910795
    [No Abstract]   [Full Text] [Related]  

  • 33. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
    Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
    J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus.
    Lindberg H; Hofström C; Altai M; Honorvar H; Wållberg H; Orlova A; Ståhl S; Gräslund T; Tolmachev V
    Tumour Biol; 2012 Jun; 33(3):641-51. PubMed ID: 22249974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IgG-Binding Nanobody Capable of Prolonging Nanobody-Based Radiotracer Plasma Half-Life and Enhancing the Efficacy of Tumor-Targeted Radionuclide Therapy.
    Hu B; Liu T; Li L; Shi L; Yao M; Li C; Ma X; Zhu H; Jia B; Wang F
    Bioconjug Chem; 2022 Jul; 33(7):1328-1339. PubMed ID: 35687724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical translation of a PSMA inhibitor for
    Ferro-Flores G; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Orocio-Rodríguez E; Davanzo J; García-Pérez FO
    Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of a New
    Farahani AM; Maleki F; Sadeghzadeh N; Abediankenari S; Abedi SM; Erfani M
    Anticancer Agents Med Chem; 2020; 20(14):1695-1703. PubMed ID: 32560611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 99mTc-labeled cystine knot peptide targeting integrin αvβ6 for tumor SPECT imaging.
    Zhu X; Li J; Hong Y; Kimura RH; Ma X; Liu H; Qin C; Hu X; Hayes TR; Benny P; Gambhir SS; Cheng Z
    Mol Pharm; 2014 Apr; 11(4):1208-17. PubMed ID: 24524409
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.